Spans structural heart (TAVR, mitral, tricuspid), electrophysiology (ablation, mapping, leadless pacing), interventional (stents, IVUS, OCT), and rhythm management (CRT, ICDs, monitors). It is one of the largest device segments by revenue, with heavy investment in minimally invasive and catheter-based therapies. Many products are Class III and need PMA approval with randomized or large single-arm trials. Coverage often depends on national coverage determinations, specialty society guidelines and registries such as the TVT Registry for transcatheter valves.

Why it matters

One of the largest, most R&D-intensive MedTech segments; long evidence cycles and dominant strategics shape competitive dynamics.

Common pitfalls

•A common pitfall is inaccurately classifying a cardiovascular device, leading to submission of inadequate regulatory documentation or an inappropriate regulatory pathway.
•Manufacturers often underestimate the necessary clinical evidence and long-term follow-up studies required for high-risk cardiovascular devices, causing delays in market authorization.
•Failing to adequately address cybersecurity risks for connected cardiovascular devices, such as pacemakers or defibrillators, can lead to significant safety vulnerabilities and regulatory non-compliance.
•Ignoring post-market surveillance requirements for cardiovascular devices can result in missed opportunities to identify safety issues and fulfill ongoing regulatory obligations.
•Incorrectly defining the device’s intended use can lead to regulatory challenges and limit market access, especially for innovative cardiovascular technologies.

Sources

ACC · American College of Cardiology
AdvaMed - Industry Reports · AdvaMed
MedTech Europe - Facts & Figures · MedTech Europe
Cardiovascular devices · U.S. Food and Drug Administration (FDA)

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.